ライフサイエンスコーパス: chemoprophylaxis

1 ation of ICU patients with high adherence to chemoprophylaxis.

2 circumcision, behavioral interventions, and chemoprophylaxis.

3 linicians need data on the safety of malaria chemoprophylaxis.

4 cluding class cancellations, quarantine, and chemoprophylaxis.

5 occus to identify candidates for intrapartum chemoprophylaxis.

6 using fourth-generation fluoroquinolones as chemoprophylaxis.

7 f whom had a history of receiving nevirapine chemoprophylaxis.

8 Both agents are effective for chemoprophylaxis.

9 t likely secondary to the longer duration of chemoprophylaxis.

10 ngst those receiving and those not receiving chemoprophylaxis.

11 carinii pneumonia is high despite widespread chemoprophylaxis.

12 mg twice daily (BID) is a common regimen for chemoprophylaxis.

13 , defined as 7 or more postoperative days of chemoprophylaxis.

14 y atovaquone/proguanil schedule for malarial chemoprophylaxis.

15 therefore potentially be used for pre-travel chemoprophylaxis.

16 ntial contributions to prevention of TB with chemoprophylaxis.

17 avelers to malarious countries still take no chemoprophylaxis.

18 t have a significant VTE risk reduction with chemoprophylaxis.

19 zinc supplementation, a bed net, and malaria chemoprophylaxis.

20 cal patients who benefit from peri-operative chemoprophylaxis.

21 VTE and/or bleeding events with and without chemoprophylaxis.

22 ficant VTE risk reduction after surgery with chemoprophylaxis.

23 linically relevant bleeding with and without chemoprophylaxis.

24 ce alone is neither superior nor inferior to chemoprophylaxis.

25 established guidelines for postdischarge VTE chemoprophylaxis.

26 ted that these patients be discharged on VTE chemoprophylaxis.

27 UFH or LMWH compared to those not receiving chemoprophylaxis (1.22 vs. 1.13%, p = .57).

28 e postoperative venous thromboembolism (VTE) chemoprophylaxis, (2) identify reasons for failure to pr

29 ention medications compared to partial or no chemoprophylaxis (20% vs 18% respectively, p = 0.49).

30 contacts, including 6001 (79%) who initiated chemoprophylaxis, 3642 (61%) who later completed treatme

31 n with relapse-causing species calls for new chemoprophylaxis acting against erythrocytic and liver s

32 e-rate ratios of inpatient and postdischarge chemoprophylaxis adherence by surgical specialty.

33 VTE events within 30 days of surgery and VTE chemoprophylaxis adherence were determined.

34 d, of whom 40,364 (97.4%) consented to begin chemoprophylaxis; adherence was 55.0% (N = 22,218) at 3-

35 ous studies have suggested the usefulness of chemoprophylaxis administered to close contacts of case-

36 d during long-term stays: discontinuation of chemoprophylaxis after the initial period, sequential re

37 M could help establish proof of concept that chemoprophylaxis against dengue is feasible.

38 ative (iPrEx), a global trial of preexposure chemoprophylaxis against human immunodeficiency virus ty

39 The increasing use of successful chemoprophylaxis against many important HIV-associated i

40 vaquone-proguanil provides effective malaria chemoprophylaxis against P. falciparum challenge at dosi

41 etroviral therapy may be able to discontinue chemoprophylaxis against Pneumocystis carinii pneumonia

42 mal changes in fecal flora, and more liberal chemoprophylaxis against this disease should be consider

43 illness in travelers, but current first-line chemoprophylaxis agents do not prevent relapses of vivax

44 Aspirin chemoprophylaxis alone cannot be considered a substitute

45 use of intermittent pneumatic compression or chemoprophylaxis alone to a combination of both treatmen

46 Selective chemoprophylaxis altering early natural exposure to mala

47 inhibitors are the mainstay of treatment and chemoprophylaxis although resistance may occur in the tr

48 It is shown that chemoprophylaxis always reduces the basic reproduction n

49 Renewed research regarding the use of chemoprophylaxis among family members of cholera cases m

50 nalysis to investigate benefits and harms of chemoprophylaxis among surgical patients individually ri

51 he need to determine an optimal duration for chemoprophylaxis among this distinct cohort.

52 I, including 22 of 6001 (0.4%) who initiated chemoprophylaxis and 24 of 1596 (1.5%) who did not initi

53 ve strategies for the selection of women for chemoprophylaxis and for the management of infants are d

54 mographic variables, co-morbidities, type of chemoprophylaxis and intraoperative factors such as use

55 Specialty and procedure variation exists for chemoprophylaxis and may be justified given the low risk

56 l malaria up to 4 years of age, adjusting by chemoprophylaxis and prior malaria exposure.

57 There was variable use of antiviral chemoprophylaxis and screening of recipients for H1N1 in

58 Several options exist for chemoprophylaxis and selection should be based on patien

59 s during prophylactic chloroquine treatment (chemoprophylaxis and sporozoites (CPS)).

60 ing chloroquine chemoprophylaxis (hereafter, chemoprophylaxis and sporozoites [CPS] immunization) ind

61 chemoprophylaxis) and pregnancy (chloroquine chemoprophylaxis and sulfadoxine-pyrimethamine intermitt

62 increased use of macrolides and rifampin for chemoprophylaxis and the treatment of subclinically affe

63 opment of new classes of antiviral drugs for chemoprophylaxis and treatment, which are urgently neede

64 einforce existing recommendations to provide chemoprophylaxis and vaccination against major preventab

65 ormidable challenge for developing effective chemoprophylaxis and vaccine approaches.

66 rmed H5N1-infected poultry without antiviral chemoprophylaxis and with minimal personal protective eq

67 and recommend which patients should receive chemoprophylaxis and with which agents.

68 eated nets, residual spraying of houses, and chemoprophylaxis) and pregnancy (chloroquine chemoprophy

69 asons for failure to provide defect-free VTE chemoprophylaxis, and (3) examine patient- and hospital-

70 d travelers, 30% and 47%, respectively, used chemoprophylaxis, and 7 (3%) and 8 (1%) were severe case

71 el and malaria prevention, long-term malaria chemoprophylaxis, and insect repellent and malaria.

72 among surgical patients who did not receive chemoprophylaxis, and patients at increased levels of Ca

73 Screening, chemoprophylaxis, and vaccination are all effective stra

74 relation was found between postoperative VTE chemoprophylaxis application and hospital specific risk

75 ment of anti-malarial vaccine candidates and chemoprophylaxis approaches that aim to prevent clinical

76 through trials of both new vaccines and new chemoprophylaxis approaches.

77 ents and several different strategies of CMV chemoprophylaxis are in practice.

78 Approaches to diagnosis, treatment, and chemoprophylaxis are now in use on the basis of these ad

79 is prevention, even when completion rates of chemoprophylaxis are suboptimal.

80 Early case detection, contact screening, and chemoprophylaxis are the most promising tools.

81 at might receive extended-duration influenza chemoprophylaxis are unknown.

82 eing developed for maintenance therapies and chemoprophylaxis, assessing virus suppression under INST

83 Antimicrobial chemoprophylaxis at time of departure and oral cholera v

84 VTE prevention in surgical patients include chemoprophylaxis based upon preoperative risk stratifica

85 Antiretroviral chemoprophylaxis before exposure is a promising approach

86 Chemoprophylaxis beginning 1 wk before departure confers

87 post-surgical patients with and without VTE chemoprophylaxis between April 2013 - September 2017 fro

88 n information, a vaccination and/or expanded chemoprophylaxis campaign was conducted in 16 (48.5%).

89 estimated glomerular filtration rate in the chemoprophylaxis cohort, 16.0 +/- 3.4 vs. 30.1 +/- 4.7 m

90 of age were measured in children undergoing chemoprophylaxis compared to children receiving placebo

91 Limited periods of exposure suggest that chemoprophylaxis could be a promising strategy to protec

92 Rates of chemoprophylaxis decreased from 16% (original protocol)

93 They consider the risks and benefits of chemoprophylaxis, discuss VTE risk stratification, and r

94 icance after adjusting for disease severity, chemoprophylaxis, drug resistance, and social determinan

95 Health authorities vary in the chemoprophylaxis drugs they recommend, the indications f

96 seriousness of malaria, the tolerability of chemoprophylaxis drugs, and the efficacy and safety of r

97 at rates comparable with or lower than other chemoprophylaxis drugs.

98 This measure assessed comprehensive VTE chemoprophylaxis during each patient's entire hospitaliz

99 ed with malaria, 71.7% had not taken malaria chemoprophylaxis during travel.

100 Disease risk and chemoprophylaxis effectiveness were estimated from publi

101 es that recommended postpartum heparin-based chemoprophylaxis (enoxaparin) based on a risk-stratified

102 y micronutrient supplementation, and malaria chemoprophylaxis every 6 wk.

103 tility of this HIV-1-based animal model in a chemoprophylaxis experiment, by showing that a commonly

104 TE-2, our novel quality measure unmasked VTE chemoprophylaxis failures in 18% of colectomies.

105 test were identified and received isoniazid chemoprophylaxis for 12 months.

106 l spraying (two rounds per year) $32-58; for chemoprophylaxis for children $3-12 (assuming an existin

107 verage to protect vaccinated individuals and chemoprophylaxis for close contacts during outbreaks.

108 rategy of short-term, oral ganciclovir-based chemoprophylaxis for CMV in liver transplant recipients

109 three major questions in optimizing malaria chemoprophylaxis for forest workers: which antimalarial

110 The use of chemoprophylaxis for high-risk patients with head and ne

111 Physicians may need to consider azole chemoprophylaxis for HIV-infected persons who live in ar

112 As a consequence, secondary chemoprophylaxis for leishmaniasis or even the use of an

113 UK public health guidelines recommend chemoprophylaxis for meningococcal eye infection cases a

114 Mefloquine is the drug of choice for chemoprophylaxis for most travelers, with doxycycline an

115 ed medical patients conditionally recommends chemoprophylaxis for non-critically ill medical inpatien

116 Clinicians should prescribe chemoprophylaxis for patients traveling to endemic regio

117 With the success of zidovudine chemoprophylaxis for prevention of perinatal transmissio

118 Rifaximin appears promising as a chemoprophylaxis for travelers' diarrhea and as a treatm

119 should include prophylaxis with antibiotics, chemoprophylaxis for venous thromboembolism, and correct

120 a regarding infections, rejection, infection chemoprophylaxis, graft failure, absolute lymphocyte cou

121 However, patients undergoing VGCV or GCV chemoprophylaxis had more leukocytopenia.

122 weekly clinic visit, but optimum duration of chemoprophylaxis has not been determined.

123 Azithromycin chemoprophylaxis has not been evaluated as a means of li

124 parum-infected mosquitoes during chloroquine chemoprophylaxis (hereafter, chemoprophylaxis and sporoz

125 ntions such as chemotherapy, vaccination and chemoprophylaxis, HIV prevalence, the age structure of t

126 Intrapartum antibiotic chemoprophylaxis (IAP) prevents most early-onset group B

127 ere more likely to receive postdischarge VTE chemoprophylaxis if undergoing rectal cancer surgery [in

128 ent specialists systematically debated about chemoprophylaxis, immunotherapy, immunization, and recom

129 l quality measure identified failures of VTE chemoprophylaxis in 0% to 3% of patients.

130 sure unmasked failure to provide defect-free chemoprophylaxis in 18% (736/4086) of colectomies.

131 ting the importance of heartworm testing and chemoprophylaxis in all dogs to reduce transmission.

132 prevent recurrent disease, such as lifelong chemoprophylaxis in HIV-1-positive tuberculosis patients

133 reduced cutpoint to determine suitability of chemoprophylaxis in HIV-seropositive persons may be prud

134 n sizes suggest eligibility for tuberculosis chemoprophylaxis in HIV-seropositive than in HIV-seroneg

135 Cases ceased following facility-wide chemoprophylaxis in July 2012.

136 Optimal timing of initiation of isoniazid chemoprophylaxis in liver transplant recipients who test

137 tes without discernible time trends, despite chemoprophylaxis in more than 80% after Year 1, and the

138 Preexposure chemoprophylaxis in only high-risk MSM can improve cost-

139 Studies are needed to evaluate if antiviral chemoprophylaxis in solid organ transplant recipients du

140 sufficient to provide adequate drug for mass chemoprophylaxis in the event of vaccine unavailability.

141 ons are needed to investigate the utility of chemoprophylaxis in this population.

142 ssess the effectiveness of this schedule for chemoprophylaxis in travelers.

143 the use of perioperative and in-hospital VTE chemoprophylaxis increased significantly from 31.6% to 8

144 The absolute risk reduction afforded by chemoprophylaxis initiation was 1.1% (95% CI, .6%-1.9%),

145 Poor compliance with chemoprophylaxis is a major contributing factor to the r

146 within 24 hours of diagnosis to ensure that chemoprophylaxis is given to all exposed persons.

147 Antiviral chemoprophylaxis is recommended for use during influenza

148 Tafenoquine chemoprophylaxis is safe and effective in preventing mal

149 ancer screening, but illustrate that aspirin chemoprophylaxis is unlikely to be associated with gains

150 e, suggesting that their wide use in topical chemoprophylaxis is unlikely.

151 ed VTE risk stratification helps ensure that chemoprophylaxis is used only in appropriate surgical pa

152 ing itinerary-tailored advice, vaccines, and chemoprophylaxis; it can also help to focus posttravel e

153 Discontinuation of PCP chemoprophylaxis may be appropriate for some HIV-infecte

154 in skilled nursing facilities, facility-wide chemoprophylaxis may be necessary to prevent sustained p

155 Pre-travel chemoprophylaxis may improve compliance by enabling "dru

156 Geographically targeted mass chemoprophylaxis might contain the spread of a pandemic

157 ng Pneumocystis isolates and by a control of chemoprophylaxis observance.

158 medications for treatment and post-exposure chemoprophylaxis of human infections with novel influenz

159 Using this model we now show that chemoprophylaxis of latently infected cynomolgus macaque

160 dels for development of additional drugs for chemoprophylaxis of liver injury and emphysema in patien

161 Tafenoquine was recently approved for chemoprophylaxis of malaria.

162 s, it constitutes an excellent candidate for chemoprophylaxis of target organ injury in alpha1-AT def

163 l approach to ascertain the causal effect of chemoprophylaxis on postinfection characteristics.

164 gistic regression, we assessed the effect of chemoprophylaxis on the incubation period, time from sym

165 The impact of chemoprophylaxis on the outcomes of infection with relap

166 or choosing the 3-day schedule over standard chemoprophylaxis options were that it was easier to reme

167 With breast-conserving therapy, chemoprophylaxis or other interventions to reduce the ra

168 participants receiving at least one dose of chemoprophylaxis or placebo were considered for safety,

169 ens, preventing first episodes of disease by chemoprophylaxis or vaccination (primary prophylaxis), a

170 Several randomized trials demonstrated that chemoprophylaxis, or low-dose anticoagulation, prevents

171 Malaria treatment, chemoprophylaxis, or other forms of parasite suppression

172 ve been preventable with appropriate advice, chemoprophylaxis, or vaccination.

173 Inpatient chemoprophylaxis ordering rates were highest for patient

174 The incorporation of prolonged-duration chemoprophylaxis (PDC) into preventive therapy has been

175 Plasmodium falciparum (Pf) sporozoites under chemoprophylaxis (PfSPZ-CVac) is the most efficacious ap

176 other-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservoirs and limits r

177 led trial showed that daily oral preexposure chemoprophylaxis (PrEP) was effective for HIV prevention

178 ylaxis rates are high, and postdischarge VTE chemoprophylaxis prescribing is similar to that of non-V

179 ous research demonstrated variability in VTE chemoprophylaxis prescribing, although it is unknown how

180 ipants aged 20-42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage Pla

181 Patients were less likely to fail the chemoprophylaxis process measure if treated at nonsafety

182 We examined adherence to a novel VTE chemoprophylaxis process measure in patients who underwe

183 Rapid initiation of a chemoprophylaxis program after 2 cases of meningococcal

184 stratified and more selective postpartum VTE chemoprophylaxis protocols.

185 iscussed: awareness of risk, bite avoidance, chemoprophylaxis, rapid diagnosis, stand-by emergency tr

186 surgery within the VHA is low, VHA inpatient chemoprophylaxis rates are high, and postdischarge VTE c

187 Implementation is hampered by a complex chemoprophylaxis regimen and missing evidence for effica

188 who did, none of the patients finished their chemoprophylaxis regimen.

189 10.6% (1399 of 13,230) were discharged on a chemoprophylaxis regimen.

190 Practical and effective chemoprophylaxis regimens for HIV-1-related tuberculosis

191 Assuming full adherence to chemoprophylaxis regimens, consultations saved healthcar

192 re not prevented with the current first-line chemoprophylaxis regimens.

193 ive measures and adhere poorly to continuous chemoprophylaxis regimens.

194 sk areas, and do not appropriately adhere to chemoprophylaxis regimens.

195 truction and while on standard postoperative chemoprophylaxis regimens.

196 inputs were varied over wide ranges, aspirin chemoprophylaxis remained generally non-cost-effective f

197 Extended-duration zanamivir and oseltamivir chemoprophylaxis seems to be highly efficacious for prev

198 tbreaks cannot be predicted, 6 months of PCP chemoprophylaxis should be considered for all RTRs and L

199 Postdischarge malaria chemoprophylaxis should be considered for SA children li

200 ens are most appropriate, how frequently the chemoprophylaxis should be delivered, and how to motivat

201 Chemoprophylaxis should be restricted to travelers who a

202 of the guidelines for selective intrapartum chemoprophylaxis (SIC) of group B streptococcal early-on

203 tial regimens with different medications for chemoprophylaxis, stand-by emergency self-treatment, and

204 meningitis in the United States despite the chemoprophylaxis strategies for preventing infection rec

205 eningitis in the USA despite CDC-recommended chemoprophylaxis strategies for preventing infection.

206 The initial chemoprophylaxis studies evaluated tenofovir administere

207 cP cases occur in those prescribed effective chemoprophylaxis, suggesting that additional preventive

208 nd-by emergency self-treatment, and seasonal chemoprophylaxis targeting high-incidence periods or loc

209 The impact of chemoprophylaxis targeting Plasmodium falciparum on Plas

210 Guidelines for travellers on malaria chemoprophylaxis, the altitude limits of dominant vector

211 mpare several national guidelines on malaria chemoprophylaxis to identify variations in recommendatio

212 h LTBI that need to be treated with standard chemoprophylaxis to prevent 1 active case.

213 nt tuberculosis infection (LTBI) are offered chemoprophylaxis to prevent active disease; however, the

214 ic analyses have examined the use of aspirin chemoprophylaxis to prevent colorectal cancer either alo

215 assay IGRA, and a positive result may prompt chemoprophylaxis to prevent progression to tuberculosis.

216 Failure to take or adhere to recommended chemoprophylaxis, to promptly seek medical care for post

217 ecember 2006 using the search terms malaria, chemoprophylaxis, travel, mefloquine, neuropsychiatric a

218 Three different treatments-chemoprophylaxis, treatment after exposure but before sy

219 e Preexposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial provided an opportunity to rigoro

220 We found data on chemoprophylaxis use in 560 patients.

221 infected with P. vivax or P. ovale reporting chemoprophylaxis use, especially of blood-stage agents,

222 r infection after transplantation, isoniazid chemoprophylaxis used during candidacy was well tolerate

223 Chemoprophylaxis users had a greater risk of presenting

224 m (Pf) sporozoites (PfSPZ) under chloroquine chemoprophylaxis, using the PfSPZ Chemoprophylaxis Vacci

225 Chemoprophylaxis vaccination with sporozoites (CVac) wit

226 Chemoprophylaxis vaccination with sporozoites (CVac) wit

227 hloroquine chemoprophylaxis, using the PfSPZ Chemoprophylaxis Vaccine (PfSPZ-CVac), induces high-leve

228 lunteers taking chloroquine for antimalarial chemoprophylaxis (vaccine approach denoted as PfSPZ-CVac

229 iable model controlled for Caprini score and chemoprophylaxis, VTE was associated with hypothermia of

230 reas who receive concurrent vaccinations and chemoprophylaxis warrant further study.

231 Chemoprophylaxis was administered in 87.0% of the women

232 of CMV syndrome or tissue-invasive disease, chemoprophylaxis was associated with a better preservati

233 ty score matched cohorts to determine if VTE chemoprophylaxis was associated with decreased VTE event

234 While postoperative VTE chemoprophylaxis was broadly applied, after adjusting fo

235 Antimicrobial chemoprophylaxis was estimated to provide the greatest p

236 ntire hospitalization, including reasons why chemoprophylaxis was not given.

237 The benefit of peri-operative VTE chemoprophylaxis was only found among surgical patients

238 Inpatient chemoprophylaxis was ordered for 24 139 patients (80.4%)

239 s in Somalia, mefloquine, a drug for malaria chemoprophylaxis, was not approved for use in pregnant w

240 resulting from traveler adherence to malaria chemoprophylaxis were calculated from 2 perspectives: th

241 Different strategies of chemoprophylaxis were compared.

242 comorbidities, operative factors as well as chemoprophylaxis were included in the analysis.

243 ion of perinatal disease through intrapartum chemoprophylaxis were revised in 2002.

244 In patients who had received chemoprophylaxis with (val-)ganciclovir (n = 63), the CM

245 regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues

246 Chemoprophylaxis with NAIs decreased the frequency of sy

247 Additionally, the efficacy of primary chemoprophylaxis with oral or topical antiretroviral reg

248 Volunteers immunized under chloroquine chemoprophylaxis with Plasmodium falciparum sporozoites

249 tion of healthy volunteers during receipt of chemoprophylaxis with Plasmodium falciparum sporozoites

250 Immunization under chemoprophylaxis with sporozoites (CPS) consistently con

251 volunteers taking chloroquine or mefloquine (chemoprophylaxis with sporozoites).

252 controlled trial in Mozambique using monthly chemoprophylaxis with sulfadoxine-pyrimethamine plus art

253 = 242) and assessed the impact of antiviral chemoprophylaxis with valganciclovir (VGCV) or ganciclov

254 While antiviral chemoprophylaxis with VGCV or GCV in patients with a hig

255 Antiviral chemoprophylaxis with VGCV or GCV in recipients with a h

256 of indirect evidence strongly suggests that chemoprophylaxis with zidovudine after exposure to HIV m

257 3142 patients (10.5%) received postdischarge chemoprophylaxis, with notable variation by specialty.

258 ized that a high rate of prescription of VTE chemoprophylaxis would be associated with decreased VTE